Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | KEYNOTE-522: EFS sensitivity & subgroup analyses

Peter Schmid, MD, PhD, FRCP, Barts Cancer Institute, London, UK, updates us on the findings of an event-free survival (EFS) sensitivity and subgroup analyses from the KEYNOTE-522 study (NCT03036488), a Phase III trial evaluating neoadjuvant pembrolizumab plus chemotherapy vs. placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo in early-stage triple-negative breast cancer (TNBC). EFS sensitivity analyses show a robust treatment benefit of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for previously untreated non-metastatic TNBC. This benefit was generally consistent across a broad selection of patient subgroups. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.